Dr. Reddy's Laboratories Ltd. (ROY) reported, under IFRS standards, that its second quarter profit attributable to equity holders of the parent company increased to INR 14.37 billion or INR 17.25 per share from INR 12.55 billion or INR 15.05 per share in the prior year.
Revenues for the quarter grew to INR 88.05 billion from INR 80.162 billion last year, driven by broad-based growth across key markets. However, the North America Generics segment faced headwinds due to heightened price erosion in select products and reduced lenalidomide sales. The recently acquired Consumer Healthcare portfolio in Nicotine Replacement Therapy (NRT) also contributed positively to overall performance.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.